FDA’s Vaccine Chief Vinay Prasad to Depart Agency Amidst Controversy
WASHINGTON — Vinay Prasad, a top official at the Food and Drug Administration (FDA) and director of the Center for Biologics Evaluation and Research (CBER), is leaving the agency for the second time in less than a year. His departure, announced on March 6, 2026, comes after a period of significant controversy surrounding the FDA’s review processes for vaccines, gene therapies, and specialty drugs.
Prasad’s Departure and FDA Response
FDA Commissioner Marty Makary informed FDA staff of Prasad’s departure in an email on Friday, stating that he will leave at the conclude of April to return to his academic position at the University of California, San Francisco [1]. Makary highlighted Prasad’s accomplishments during his tenure, including efforts to reduce clinical trial requirements for drug approvals, refine COVID-19 vaccine approvals, and establish pathways for individualized medicines [1]. The agency intends to name a successor before his departure [4].
A History of Controversy
Prasad’s first departure from the FDA occurred in July 2025, following criticism from rare disease advocates and conservative influencer Laura Loomer regarding his handling of a treatment for Duchenne muscular dystrophy [3]. He was reinstated shortly after with the support of Health Secretary Robert F. Kennedy Jr. And Commissioner Makary.
Increased Scrutiny of Rare Disease Drugs
Under Prasad’s leadership, CBER increased scrutiny of rare disease drugs, even as Makary publicly emphasized regulatory flexibility. This led to the rejection of at least five cell and gene therapies that experts believed would have been approved under previous FDA leadership [1]. Drugmakers have accused the agency of reversing previous agreements regarding clinical trial designs, citing instances where approvals were jeopardized due to concerns about clinical data previously considered acceptable [1].
Recent Conflicts and Decisions
Recent controversies include Prasad’s initial refusal to allow FDA review of a new mRNA flu vaccine from Moderna, a decision that ultimately required White House intervention [1]. He likewise reportedly overruled staff to halt vaccine surveillance, raising concerns among 12 former FDA commissioners who suggested his regulatory approach might hinder the development of new vaccines [2].
Broader Trends at the FDA
Prasad’s departure is part of a larger trend of turnover among top FDA officials. The Center for Drug Evaluation and Research experienced five different directors in 2025, with several departures attributed to concerns about political interference in the agency’s scientific processes [3].
Management Style Concerns
Reports indicate that Prasad’s management style created a challenging operate environment. Eight agency officials told STAT in October that Prasad fostered mistrust and paranoia [1]. He reportedly required staff to share their calendars while keeping his own private and discouraged direct communication with supervisors.